Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.50−0.11 (-1.96%)
Close on Nov 18, 2026Market cap $282.00MP/E –Yield –
Emergent BioSolutions net income
Net income is the profit left for shareholders after every expense, interest and tax.
Emergent BioSolutions's net income for the twelve months ending Sep 30, 2026 was -$260.70M, down 443.5% year over year. For fiscal 2025 it was $52.60M. Over ten years it grew -1.8% a year on average. The highest annual figure on record is $305.80M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.60M | – |
| FY2024 | Dec 31, 2024 | -$190.60M | – |
| FY2023 | Dec 31, 2023 | -$760.50M | – |
| FY2022 | Dec 31, 2022 | -$211.60M | -196.4% |
| FY2021 | Dec 31, 2021 | $219.50M | -28.2% |
| FY2020 | Dec 31, 2020 | $305.80M | +461.1% |
| FY2019 | Dec 31, 2019 | $54.50M | -13.1% |
| FY2018 | Dec 31, 2018 | $62.70M | -24.1% |
| FY2017 | Dec 31, 2017 | $82.60M | +59.5% |
| FY2016 | Dec 31, 2016 | $51.80M | -17.6% |
| FY2015 | Dec 31, 2015 | $62.87M | +71.1% |
| FY2014 | Dec 31, 2014 | $36.74M | +18.0% |
| FY2013 | Dec 31, 2013 | $31.14M | +32.4% |
| FY2012 | Dec 31, 2012 | $23.52M | +2.2% |
| FY2011 | Dec 31, 2011 | $23.02M | -55.5% |
| FY2010 | Dec 31, 2010 | $51.70M | +66.0% |
| FY2009 | Dec 31, 2009 | $31.14M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$32.70M | -163.9% |
| Q2 FY2026 | Jun 30, 2026 | -$180.20M | – |
| Q1 FY2026 | Mar 31, 2026 | $6.80M | -90.0% |
| Q4 FY2025 | Dec 31, 2025 | -$54.60M | – |
| Q3 FY2025 | Sep 30, 2025 | $51.20M | -55.4% |
| Q2 FY2025 | Jun 30, 2025 | -$12.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $68.00M | +655.6% |
| Q4 FY2024 | Dec 31, 2024 | -$31.30M | – |
| Q3 FY2024 | Sep 30, 2024 | $114.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$283.10M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$49.50M | – |
| Q3 FY2023 | Sep 30, 2023 | -$263.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$261.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$186.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$67.00M | -134.7% |
| Q3 FY2022 | Sep 30, 2022 | -$87.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$52.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.60M | -106.8% |
| Q4 FY2021 | Dec 31, 2021 | $193.10M | +4.2% |
| Q3 FY2021 | Sep 30, 2021 | -$40.40M | -202.3% |
| Q2 FY2021 | Jun 30, 2021 | -$500.00K | -100.5% |
| Q1 FY2021 | Mar 31, 2021 | $67.30M | – |
| Q4 FY2020 | Dec 31, 2020 | $185.40M | +295.3% |
| Q3 FY2020 | Sep 30, 2020 | $39.50M | -8.6% |
| Q2 FY2020 | Jun 30, 2020 | $92.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $46.90M | – |
| Q3 FY2019 | Sep 30, 2019 | $43.20M | +106.7% |
| Q2 FY2019 | Jun 30, 2019 | -$9.50M | -119.0% |
| Q1 FY2019 | Mar 31, 2019 | -$26.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.40M | -110.0% |
| Q3 FY2018 | Sep 30, 2018 | $20.90M | -37.7% |
| Q2 FY2018 | Jun 30, 2018 | $50.10M | +985.4% |
| Q1 FY2018 | Mar 31, 2018 | -$4.90M | -146.7% |
| Q4 FY2017 | Dec 31, 2017 | $33.95M | -9.3% |
| Q3 FY2017 | Sep 30, 2017 | $33.55M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.62M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $37.42M | – |
See a number that looks wrong?